Key Highlights
- Shares surged 54.76% over the week, closing at $42.08, including a 35.70% single day gain at Friday's close from a prior close of $31.01.
- Second quarter Revenue rose 48% year over year to $64.1 million, with gross Margin expanding to 83.0% from 75.5%.
- The company raised full year 2026 revenue guidance to $246 million to $250 million, up from a prior range of $228 million to $232 million.
- Heartflow revenue cases grew to 84,491 in the second quarter, up from 48,423 a year earlier, driven partly by expanded Medicare reimbursement for its Plaque Analysis product.
A Post-IPO Growth Stock Delivers a Blowout Quarter
Heartflow, Inc. (NASDAQ:HTFL) shares surged 54.76% over the week to close at $42.08, with more than half of that gain concentrated in a single 35.70% jump on Friday's close following its second quarter Earnings release. The San Francisco based commercial stage medical technology company, whose AI platform analyzes coronary CT angiography scans to help physicians diagnose and manage coronary artery disease, completed its initial public offering just over a year ago in August 2025.
The scale of the single day move reflected a quarter that beat expectations across nearly every metric, from revenue growth to margin expansion to forward guidance, a combination that can produce outsized reactions in recently public growth companies with still-developing analyst coverage.
Revenue Growth Accelerated on Plaque Analysis Adoption
Second quarter revenue reached $64.1 million, up 48% from $43.4 million a year earlier, driven by a 74% increase in revenue case Volume that offset a lower average selling price tied to a higher mix of clinic and office based accounts. Gross margin expanded to 83.0% from 75.5%, aided by increased revenue case volume and improved production team productivity from AI efficiency initiatives.
Much of the acceleration traced to the company's Plaque Analysis product, which gained expanded Medicare Administrative Contractor reimbursement coverage under a new CPT code effective January 2026. Total Heartflow revenue cases climbed to 84,491 in the quarter from 48,423 a year earlier, an increase the company attributed to continued adoption of both its established FFRCT Analysis and its newer Plaque Analysis offering. Operating expenses rose to $71.1 million from $46.5 million, reflecting increased Investment in sales personnel, technology, and clinical research supporting the broader commercial push.
Balancing Accelerating Growth Against Ongoing Losses and Regulatory Scrutiny
The durability of this week's rally will likely depend on whether Plaque Analysis adoption continues to scale as new accounts activate and existing accounts expand utilization, since the product remains in relatively early stages of its reimbursement ramp. The company disclosed that it and certain employees received civil investigative demands from the U.S. Department of Justice in October 2025 related to an ongoing Anti-Kickback Statute and False Claims Act investigation, a matter still unresolved as of this filing that could carry financial or reputational implications depending on its outcome.
On the upside, the company's raised full year guidance, now calling for 40% to 42% revenue growth compared to a prior outlook of 29% to 32%, signals management's confidence that the quarter's momentum extends through the balance of 2026, and a $246.8 million cash position provides runway to fund continued investment. Conversely, Heartflow remains unprofitable on a GAAP basis, posting a net loss of $15.7 million for the quarter, and continued heavy investment in sales and Research and Development means a clear path to sustained profitability has not yet been demonstrated.
Conclusion
Heartflow's 54.76% weekly advance, anchored by a 35.70% single day surge on Friday, reflects investor enthusiasm following a quarter that combined accelerating revenue growth, expanding margins, and raised guidance. Whether the rally holds will likely depend on continued Plaque Analysis adoption and the eventual resolution of the pending Department of Justice investigation, neither of which is yet settled. The reaction illustrates how sharply newly public growth companies can reprice when a strong quarter validates the broader growth thesis behind their public listing.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...